A Phase II Study of Erlotinib for previously treated Non-Small Cell Lung Cancer Patients
- Conditions
- Objective of the study is to investigate efficacy and safety of Erlotinib for previously treated non-small cell lung cancer patients.
- Registration Number
- JPRN-UMIN000004680
- Lead Sponsor
- Tottori University, Faculty of Medicine,Division of Medical Oncology and Molecular Respirology Department of Multidisciplinary Internal Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 27
Not provided
1) Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, or drug-induced pneumonitis. 2) Patients with massive pleural or pericardial effusion,or ascites. 3) Patients with active severe infections. 4) Cases with past history of administration of HER related agents(gefitinib,trastuzumab,lapatinib,cetuximab). 5) Impossible cases with oral administration. 6) Patients with active opthalmological disease. 7) Pregnancy or lactation. 8) Patients with symptomatic brain metastasis. 9) Patients with active concomitant malignancy. 10) Patients with uncontrollabe diabetes mellitus. 11) Patients with uncontrollable complications. 12) Inappropriate patients for this study judged by the physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response Rate
- Secondary Outcome Measures
Name Time Method Disease Control Rate,Progression Free Survival,Overall Survival,evaluation of safety